UBX
Income statement / Annual
Last year (2023), Unity Biotechnology, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Unity Biotechnology, Inc.'s net income was -$39.86 M.
See Unity Biotechnology, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$236,000.00
|
$4.78 M
|
$0.00
|
$0.00
|
$0.00
|
$1.38 M
|
$0.00
|
| Cost of Revenue |
$19.70 M |
$2.18 M |
$2.88 M |
$3.45 M |
$2.66 M |
$2.18 M |
$37.37 M |
$153,000.00 |
| Gross Profit |
-$19.70 M |
-$1.94 M |
$1.90 M |
-$3.45 M |
-$2.66 M |
-$2.18 M |
-$35.99 M |
-$153,000.00 |
| Gross Profit Ratio |
0 |
-8.24 |
0.4 |
0 |
0 |
0 |
-26.04 |
0 |
| Research and Development
Expenses |
$20.10 M
|
$36.86 M
|
$38.39 M
|
$67.31 M
|
$70.96 M
|
$58.91 M
|
$37.37 M
|
$13.71 M
|
| General & Administrative
Expenses |
$18.77 M
|
$20.95 M
|
$23.06 M
|
$24.03 M
|
$20.05 M
|
$16.02 M
|
$9.62 M
|
$5.14 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.77 M
|
$20.95 M
|
$23.06 M
|
$24.03 M
|
$20.05 M
|
$16.02 M
|
$9.62 M
|
$5.14 M
|
| Other Expenses |
$5.60 M |
-$17,000.00 |
-$983,000.00 |
$182,000.00 |
$4.19 M |
-$245,000.00 |
-$103,000.00 |
$0.00 |
| Operating Expenses |
$44.67 M |
$57.81 M |
$61.45 M |
$91.33 M |
$91.00 M |
$74.92 M |
$46.99 M |
$18.84 M |
| Cost And Expenses |
$44.67 M |
$57.81 M |
$61.45 M |
$91.33 M |
$91.00 M |
$74.92 M |
$46.99 M |
$18.84 M |
| Interest Income |
$422,000.00 |
$1.22 M |
$100,000.00 |
$1.20 M |
$3.29 M |
$3.31 M |
$1.06 M |
$0.00 |
| Interest Expense |
$0.00 |
$3.56 M |
$3.18 M |
$1.29 M |
$0.00 |
$3.31 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.18 M
|
$2.18 M
|
$2.88 M
|
$3.45 M
|
$2.66 M
|
$2.18 M
|
$1.30 M
|
$153,000.00
|
| EBITDA |
-$37.28 M
|
-$38.73 M
|
-$54.67 M
|
-$89.10 M
|
-$89.65 M
|
-$74.22 M
|
-$44.30 M
|
-$28.07 M
|
| EBITDA Ratio |
0 |
-238.85 |
-12.03 |
0 |
0 |
0 |
-32.06 |
0 |
| Operating Income Ratio
|
0
|
-243.95
|
-11.84
|
0
|
0
|
0
|
-33
|
0
|
| Total Other
Income/Expenses Net |
$4.81 M
|
$13.10 M
|
-$4.06 M
|
$86,000.00
|
$7.47 M
|
$3.07 M
|
$952,000.00
|
-$11.56 M
|
| Income Before Tax |
-$39.86 M |
-$59.93 M |
-$60.73 M |
-$93.84 M |
-$82.18 M |
-$76.40 M |
-$44.66 M |
-$30.40 M |
| Income Before Tax Ratio
|
0
|
-253.93
|
-12.69
|
0
|
0
|
0
|
-32.31
|
0
|
| Income Tax Expense |
$0.00 |
-$2.18 M |
-$686,000.00 |
-$1.98 M |
-$7.30 M |
$3.07 M |
-$1.06 M |
$11.56 M |
| Net Income |
-$39.86 M |
-$57.75 M |
-$60.04 M |
-$91.87 M |
-$74.87 M |
-$76.40 M |
-$44.66 M |
-$30.40 M |
| Net Income Ratio |
0 |
-244.69 |
-12.55 |
0 |
0 |
0 |
-32.31 |
0 |
| EPS |
-2.7 |
-6.08 |
-10.76 |
-18.06 |
-17.16 |
-27.02 |
-129.91 |
-88.45 |
| EPS Diluted |
-2.7 |
-6.08 |
-10.76 |
-18.06 |
-17.16 |
-27.02 |
-129.91 |
-88.45 |
| Weighted Average Shares
Out |
$14.77 M
|
$9.49 M
|
$5.58 M
|
$5.09 M
|
$4.36 M
|
$2.83 M
|
$343,734.00
|
$343,734.00
|
| Weighted Average Shares
Out Diluted |
$14.77 M
|
$9.49 M
|
$5.58 M
|
$5.09 M
|
$4.36 M
|
$2.83 M
|
$343,734.00
|
$343,734.00
|
| Link |
|
|
|
|
|
|
|
|
